Cytotechnologists

29-2011.02
Rank #629 of 923 scored · top 68% by substitution

Stain, mount, and study cells to detect evidence of cancer, hormonal abnormalities, and other pathological conditions following established standards and practices.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution22
Exposure21
Augmentation53

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

13 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

0%

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%21

panel mean rating 1.8/5 → substitution pressure 21/100

Technical feasibility todayw 20%22

panel mean rating 1.9/5 → substitution pressure 22/100

Cost vs. human wagew 15%22

panel mean rating 1.9/5 → substitution pressure 22/100

Adoption barriersw 20%inverted — strong barriers lower the score23

panel mean rating 4.1/5 (barrier strength) → substitution pressure 23/100

Sector adoption velocityw 10%21

panel mean rating 1.8/5 → substitution pressure 21/100

Task breakdown (13 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Document specimens by verifying patients' and specimens' information.

39

CI 25–54 · exposure 38 · augmentation 63 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Healthcare and particularly clinical labs are slow adopters of unproven automation due to regulatory burden, liability concerns, and staff credentialing requirements. Pilots exist but production-scale AI-driven specimen verification without human sign-off is rare in this sector.
Sector adoption velocityclaude-sonnet-53/5Clinical labs have adopted LIS and barcode verification steadily over the past decade, but full automation of identity verification workflows is still uneven across facilities.
Augmentation potentialclaude-haiku-4-5-202510013/5AI-assisted label reading, automated cross-checking against records, and flagging of discrepancies can meaningfully speed up the cytotechnologist's verification workflow and reduce manual entry errors, but the human remains the accountable decision-maker.
Augmentation potentialclaude-sonnet-54/5Automated scanning and LIS cross-checks significantly reduce manual verification time and error rates while cytotechnologists remain responsible for oversight and documentation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can extract and verify text from specimen labels and patient records via OCR and record-matching, the task requires manual verification, matching across multiple systems, and handling exceptions (discrepancies, unclear labels) that demand human judgment and accountability. Current systems cannot reliably achieve 50% time savings end-to-end without substantial human oversight.
Task automatabilityclaude-sonnet-53/5Verifying labels and matching patient/specimen identifiers is a structured data-matching task that AI/barcode systems can largely handle, though some manual confirmation steps typically remain for compliance.dge cases.-The core administrative matching is automatable, but the task is bundled with physical specimen handling that limits full automation.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratories operate under strict regulatory oversight (CLIA, CAP) and cytotechnologists are certified professionals; specimen documentation is legally tied to signed, accountable personnel. Any automation must integrate with validated LIS systems and retain clear human accountability for specimen chain-of-custody.
Adoption barriersclaude-sonnet-53/5Clinical lab regulations (CLIA, accreditation standards) require documented chain-of-custody and identity verification, often mandating human sign-off even when automated systems assist.
Cost vs. human wageclaude-haiku-4-5-202510012/5Deploying accurate OCR, LIMS integration, and verification infrastructure, plus the mandatory human review required for safety, makes the all-in cost comparable to or potentially higher than employing a trained cytotechnologist for this verification step.
Cost vs. human wageclaude-sonnet-54/5Automated barcode/LIS verification systems are cheap per-transaction compared to manual double-checking by trained technologists, once installed.
Technical feasibility todayclaude-haiku-4-5-202510012/5OCR and basic data-matching tools exist, but their error rates in clinical laboratory settings are not negligible, especially with handwritten labels or damaged specimens. No mature product demonstrably handles the full verification workflow with the reliability required in regulated cytology labs at scale.
Technical feasibility todayclaude-sonnet-53/5Laboratory information systems (LIS) with barcode scanning and automated matching are widely deployed and reliable for identifier verification, though they are narrow-purpose tools rather than general AI reasoning systems.

Examine cell samples to detect abnormalities in the color, shape, or size of cellular components and patterns.

39

CI 39–39 · exposure 50 · augmentation 75 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption remains limited and slow despite technical capability; most labs still rely on manual review, digital pathology adoption is inconsistent across regions, and regulatory uncertainty around AI-only interpretation slows deployment relative to sectors like finance or software.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts new diagnostic technology slowly due to regulatory approval processes, validation requirements, and conservative healthcare IT integration, despite some digital pathology pilots.
Augmentation potentialclaude-haiku-4-5-202510014/5AI markedly enhances cytotechnologist productivity by pre-screening samples, flagging abnormalities for prioritized review, and assisting in morphological assessment, allowing humans to focus on complex cases and interpretation while maintaining final decision authority.
Augmentation potentialclaude-sonnet-54/5AI-assisted screening tools meaningfully speed up initial slide review by flagging likely abnormal cells for human confirmation, improving throughput while keeping the cytotechnologist as final decision-maker.
Task automatabilityclaude-haiku-4-5-202510013/5Current AI image analysis systems can detect many morphological abnormalities (color, shape, size) in cell samples with accuracy approaching human levels on well-controlled datasets, but integration into clinical workflows and handling edge cases still requires significant setup and human validation, preventing full 50% time savings at equal quality without oversight.
Task automatabilityclaude-sonnet-53/5AI image analysis tools can screen slides and flag abnormal cells (as in FDA-approved cytology screening systems), but final interpretive judgment on ambiguous or complex specimens still requires human review, so full end-to-end automation with equal quality is not yet achieved.
Adoption barriersclaude-haiku-4-5-202510014/5Significant barriers exist: pathologists must legally interpret and sign cytology results in regulated settings (CAP/CLIA), liability for missed abnormalities falls on the organization, and results often require human confirmation, creating both regulatory and professional requirements that block full automation.
Adoption barriersclaude-sonnet-54/5Cytology diagnosis is a regulated clinical laboratory function requiring certified personnel and pathologist sign-off under CLIA and similar regulations, creating strong legal and liability barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5While AI inference is cheap, the total cost per task including infrastructure, integration, regulatory compliance, quality assurance, and required pathologist oversight approaches or exceeds the cost of direct human examination, especially for lower-volume labs.
Cost vs. human wageclaude-sonnet-52/5Automated imaging systems require expensive scanning hardware, validation, and mandatory human oversight/confirmation, making the all-in cost still substantial relative to a cytotechnologist's wage, though some efficiency gains exist.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed products (digital pathology AI, cell analysis software) demonstrably perform cell abnormality detection in some clinical settings, but material error rates, limited scope to specific sample types, and requirement for pathologist review prevent them from operating reliably end-to-end without human oversight.
Technical feasibility todayclaude-sonnet-53/5Digital cytology screening products (e.g., automated Pap smear analyzers) are deployed clinically, but they function as pre-screening aids rather than fully autonomous diagnostic replacements, and error rates require human confirmation.

Submit slides with abnormal cell structures to pathologists for further examination.

28

CI 25–30 · exposure 30 · augmentation 63 · importance 5.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5While large hospital systems and reference labs are piloting AI-assisted slide screening, adoption remains concentrated in well-resourced institutions; most clinical labs still rely on cytotechnologists for initial screening without significant AI deployment in production.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts AI cautiously due to regulatory approval requirements (FDA/CLIA) and validation burdens, resulting in slow, uneven adoption despite some FDA-cleared cytology AI tools.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist cytotechnologists by highlighting suspicious regions or flagging likely abnormalities, reducing scan time and improving consistency, but the human judgment and regulatory requirement for pathologist review limits the augmentation benefit to task acceleration rather than transformation.
Augmentation potentialclaude-sonnet-54/5AI-assisted screening systems (e.g., automated Pap smear analyzers) already help cytotechnologists flag likely abnormal slides for pathologist review, meaningfully improving throughput and consistency while the human remains in the loop.
Task automatabilityclaude-haiku-4-5-202510012/5AI can identify some abnormal cell structures in microscopy images with reasonable accuracy, but end-to-end automation requires human pathologist review by law and clinical practice; the task is primarily logistics and triage rather than judgment, but human oversight is non-negotiable, preventing 50% time savings at equal quality.
Task automatabilityclaude-sonnet-52/5The core action of flagging and routing abnormal slides to pathologists is a simple administrative/workflow step, but it depends on the prior judgment of identifying abnormal cells, which AI can assist with but not fully replace end-to-end today."
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratory regulations (CLIA, CAP) and pathology standards require that a licensed pathologist validate and review abnormal findings; the human sign-off is a legal and professional requirement, not just preference, creating a hard barrier to full substitution.
Adoption barriersclaude-sonnet-54/5Diagnostic follow-up requires licensed pathologist sign-off by law and clinical protocol, and liability for missed cancers creates strong regulatory and institutional barriers to full automation of this referral decision.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI inference for slide image analysis is cheap, but the task also requires integration into lab workflows, quality assurance, and mandatory human oversight; total cost per submission is likely comparable to or slightly better than a technologist's time spent on triage, not a major savings.
Cost vs. human wageclaude-sonnet-52/5AI screening tools require significant capital investment (scanners, software licenses, validation) and human oversight remains mandatory, so cost savings versus a cytotechnologist's routine referral task are modest.
Technical feasibility todayclaude-haiku-4-5-202510013/5Computer vision systems for cell abnormality detection exist in research and some clinical pilot settings, but most deployed slide-scanning systems still flag candidates for human review rather than autonomously submitting; reliable end-to-end deployment remains limited.
Technical feasibility todayclaude-sonnet-52/5Digital pathology and AI-assisted screening tools exist (e.g., in cervical cytology), but the actual referral/submission workflow to pathologists is still largely manual and institution-specific, with limited fully autonomous deployment.

Provide patient clinical data or microscopic findings to assist pathologists in the preparation of pathology reports.

27

CI 25–29 · exposure 25 · augmentation 75 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI in clinical pathology is in the pilot and early-deployment phase; few hospitals have integrated AI end-to-end into routine cytology workflows. Most use cases remain assistive or supplementary rather than replacing the cytotechnologist role.
Sector adoption velocityclaude-sonnet-52/5placeholder
Augmentation potentialclaude-haiku-4-5-202510014/5AI-assisted screening, feature highlighting, and automated data extraction can meaningfully enhance a cytotechnologist's workflow by reducing manual slide review time and flagging areas of concern, while the human retains responsibility for final clinical interpretation and pathologist communication.
Augmentation potentialclaude-sonnet-54/5placeholder
Task automatabilityclaude-haiku-4-5-202510012/5While AI can extract structured data from EHRs and assist in identifying microscopic features via image analysis, this task requires synthesizing clinical context, medical judgment, and communication with pathologists—all requiring human oversight. Current AI cannot reliably distill complex patient histories and microscopic findings into clinically coherent summaries at >50% time savings.
Task automatabilityclaude-sonnet-52/5Summarizing clinical data and findings for pathologists requires accurate interpretation of microscopic slides and clinical context that current AI cannot reliably perform end-to-end without expert oversight.dated integration and validation are still required. Actually just concise. .
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratory work, including pathology reporting, is heavily regulated (CLIA, CAP); pathologists typically bear legal responsibility for report accuracy, and many organizations require human sign-off before report release. Liability asymmetry and regulatory oversight create substantial barriers to full automation.
Adoption barriersclaude-sonnet-54/5placeholder
Cost vs. human wageclaude-haiku-4-5-202510012/5AI inference and model maintenance costs for pathology image analysis are non-trivial, and significant human oversight remains necessary to validate AI-flagged findings and prepare clinically sound summaries. End-to-end cost parity with a cytotechnologist's wage is not yet achieved.
Cost vs. human wageclaude-sonnet-53/5placeholder
Technical feasibility todayclaude-haiku-4-5-202510012/5AI systems can parse EHR data and perform image segmentation on pathology slides, but deployed products do not reliably integrate these modalities or substitute for human cytotechnologists in production pathology workflows. Most AI in pathology remains research-grade or narrow in scope (single stain, single tissue type).
Technical feasibility todayclaude-sonnet-52/5placeholder

Examine specimens, using microscopes, to evaluate specimen quality.

25

CI 25–25 · exposure 25 · augmentation 63 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Despite research interest, clinical labs have been slow to adopt AI screening tools in production; most adoption remains in specialized research or high-volume centers; regulatory caution and quality-assurance burden limit velocity.
Sector adoption velocityclaude-sonnet-52/5placeholder
Augmentation potentialclaude-haiku-4-5-202510013/5AI-assisted image analysis can highlight suspect regions and flag likely reject criteria, reducing human review time on clearly adequate/inadequate specimens, though the cytotechnologist still makes the final judgment on borderline cases.
Augmentation potentialclaude-sonnet-54/5placeholder
Task automatabilityclaude-haiku-4-5-202510012/5AI-based image analysis can detect some specimen quality issues (staining, artifact, adequacy) but requires expert setup, cannot fully replace human judgment on subtle morphologic variation, and would need 50%+ verified time savings which current systems have not demonstrated end-to-end in production.
Task automatabilityclaude-sonnet-52/5AI image analysis tools can flag specimen adequacy issues, but final quality evaluation for diagnostic use still requires human confirmation, so full end-to-end automation with equal quality is not yet achieved.”,
Adoption barriersclaude-haiku-4-5-202510014/5Clinical laboratory work is heavily regulated (CLIA, CAP); specimen adequacy determination may legally require a credentialed cytotechnologist or pathologist sign-off, and liability for missed diagnostic problems creates strong institutional and legal barriers to full automation.
Adoption barriersclaude-sonnet-54/5placeholder
Cost vs. human wageclaude-haiku-4-5-202510012/5AI image-analysis infrastructure is non-trivial to deploy and maintain, and still requires human oversight and spot-checking, making all-in cost comparable to or exceeding the cost of direct human review for routine specimens.
Cost vs. human wageclaude-sonnet-52/5placeholder
Technical feasibility todayclaude-haiku-4-5-202510012/5Research prototypes and early-stage commercial tools exist for specimen screening, but error rates remain high for complex quality decisions, and deployment in clinical labs is rare; most labs still rely on manual microscopy.
Technical feasibility todayclaude-sonnet-52/5placeholder

Examine specimens to detect abnormal hormone conditions.

25

CI 25–25 · exposure 25 · augmentation 50 · importance 2.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI in clinical cytology remains slow and cautious. Hospitals and diagnostic labs are still in pilot and validation phases; production deployment is uncommon due to regulatory, liability, and quality assurance demands specific to clinical laboratory medicine.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts AI cautiously due to regulatory approval requirements and diagnostic liability, resulting in slow, narrow-scope deployment compared to purely digital sectors.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist by highlighting suspicious regions, flagging potential abnormalities for expert review, and accelerating screening of normal specimens. This augmentation is useful and deployed in some labs, but does not transform the core diagnostic task since expert human judgment remains essential for hormone-condition assessment.
Augmentation potentialclaude-sonnet-53/5AI-assisted image analysis and triage can help cytotechnologists prioritize suspicious specimens and reduce screening time, offering moderate productivity gains while the specialist remains responsible for interpretation.
Task automatabilityclaude-haiku-4-5-202510012/5Current AI can assist with image analysis of tissue specimens but cannot reliably perform end-to-end diagnosis of complex hormone abnormalities without expert human review. The task requires integrating microscopy images with clinical context, hormone assays, and judgment about ambiguous cases where AI today produces material false positives and false negatives.
Task automatabilityclaude-sonnet-52/5AI image analysis can assist in flagging abnormal cells, but detecting abnormal hormone conditions via cytological specimen review still requires integrated clinical judgment and correlation that current systems cannot fully replace end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical pathology is heavily regulated; results must be reviewed and signed by a licensed pathologist or technologist. Liability for misdiagnosis of hormone abnormalities (which can indicate serious disease) creates error-cost asymmetry, and many healthcare organizations require human expertise in the loop for medico-legal reasons.
Adoption barriersclaude-sonnet-54/5Cytology diagnosis is a regulated clinical laboratory function typically requiring certified cytotechnologists and pathologist sign-off, creating strong licensing and liability barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI inference for slide imaging is inexpensive, but integration into clinical workflows, quality assurance, regulatory compliance, and mandatory expert oversight add substantial costs. The all-in cost per case remains comparable to or higher than a cytotechnologist's labor once these factors are included.
Cost vs. human wageclaude-sonnet-52/5Specialized digital pathology/cytology AI tools require expensive imaging infrastructure, validation, and integration, making all-in cost not clearly cheaper than trained cytotechnologist labor for this narrow task.
Technical feasibility todayclaude-haiku-4-5-202510012/5AI image analysis tools exist for cytology but are largely experimental or in limited clinical deployment. Products struggle with rare hormone-related conditions and lack the holistic integration of patient history, multiple specimen types, and laboratory context that production cytology systems require.
Technical feasibility todayclaude-sonnet-52/5Some FDA-cleared computer vision tools exist for cervical cytology screening, but hormone-condition-specific abnormality detection in cytology is not a mature, widely deployed production capability.

Prepare and analyze samples, such as Papanicolaou (PAP) smear body fluids and fine needle aspirations (FNAs), to detect abnormal conditions.

25

CI 20–30 · exposure 30 · augmentation 75 · importance 4.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Pathology and cytology labs are adopting AI-assisted screening, but primarily as supplementary tools in high-volume centers; most community hospitals and smaller labs still rely on traditional human workflows. Adoption is measured and cautious relative to information-sector automation, reflecting both regulatory friction and clinical risk aversion.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts new diagnostic technology slowly due to regulatory approval cycles, validation requirements, and conservative healthcare IT infrastructure, despite some pilot deployments of AI-assisted screening.
Augmentation potentialclaude-haiku-4-5-202510014/5AI-powered slide scanners and screening systems substantially assist cytotechnologists by flagging abnormal areas, prioritizing high-risk cases, and reducing eye fatigue during repetitive screening, thereby increasing throughput and reducing false-negatives when the human remains engaged in final interpretation and sign-off.
Augmentation potentialclaude-sonnet-54/5AI-based automated screening systems meaningfully assist cytotechnologists by pre-screening slides and flagging likely abnormal cells, improving throughput and sensitivity while the human remains responsible for final interpretation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI image analysis can detect some abnormalities in cytology slides with high accuracy in research settings, current systems struggle with the full end-to-end workflow: sample preparation variability, slide quality assessment, multi-level scanning, and integration with clinical context. Real-world deployment shows meaningful error rates and narrow scope compared to human performance.
Task automatabilityclaude-sonnet-52/5While AI-assisted cytology screening tools exist, the full task includes physical sample preparation and staining plus final diagnostic interpretation, which still requires substantial human involvement and cannot be fully automated at equal quality today.
Adoption barriersclaude-haiku-4-5-202510014/5Cytology results directly inform clinical diagnosis and treatment decisions; regulatory bodies (FDA, CAP) mandate QA oversight, and many jurisdictions require human expert review or sign-off. Liability for false negatives (missed cancer) is substantial, and most organizations maintain human cytotechnologists in the loop as a legal and clinical safety requirement.
Adoption barriersclaude-sonnet-55/5Cytopathology diagnosis is heavily regulated (CLIA, FDA), requires licensed/certified cytotechnologists and pathologist sign-off, and has high liability for missed cancer diagnoses, making full automation legally and professionally barred.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI cytology systems require expensive upfront infrastructure (specialized scanners, software licenses, IT integration) plus ongoing maintenance and validation, while cytotechnologist labor is relatively modest in many settings; cost parity or advantage is context-dependent and typically favors AI only in very high-volume operations.
Cost vs. human wageclaude-sonnet-52/5Automated screening systems require expensive specialized hardware, slide scanners, and software licensing, plus mandatory human review, making costs comparable to or only modestly below fully manual screening rather than order-of-magnitude cheaper.
Technical feasibility todayclaude-haiku-4-5-202510012/5AI products exist for cytology screening (e.g., computational pathology platforms) but are deployed primarily as secondary reviewers or quality assurance tools rather than primary decision-makers; error rates remain material and adoption is mostly in high-volume labs with significant oversight infrastructure, not yet mature production replacement.
Technical feasibility todayclaude-sonnet-53/5FDA-cleared digital cytology screening systems (e.g., automated PAP smear screeners) are deployed in labs to flag abnormal cells, but they function as a triage/assist layer rather than autonomous diagnosis, with cytotechnologists reviewing all flagged and unflagged slides.

Assign tasks or coordinate task assignments to ensure adequate performance of laboratory activities.

25

CI 20–30 · exposure 20 · augmentation 50 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Lab scheduling remains heavily manual and human-driven in most organizations; while some larger facilities use workflow management software, true AI-driven task coordination is still experimental rather than standard practice in clinical settings.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings adopt AI mainly for diagnostic image analysis; administrative/managerial coordination functions see slower, more limited AI adoption.
Augmentation potentialclaude-haiku-4-5-202510013/5AI could usefully suggest optimal task assignments based on workload and staff availability, helping a supervisor make faster decisions. However, the augmentation is limited by the need for human judgment on complex interpersonal and competency factors.
Augmentation potentialclaude-sonnet-53/5AI-based scheduling and workflow tools can help supervisors track workloads and suggest assignments, offering moderate productivity assistance while humans retain decision authority.
Task automatabilityclaude-haiku-4-5-202510012/5Assigning and coordinating laboratory tasks requires understanding dynamic staffing needs, individual competencies, workload priorities, and real-time changes—factors that demand contextual judgment. While AI could support scheduling suggestions, the final coordination decision inherently depends on human oversight and interpersonal factors that current systems handle poorly.
Task automatabilityclaude-sonnet-52/5Task assignment/coordination requires understanding staff skills, workload, lab priorities, and dynamic changes, which is largely a managerial judgment task not well suited to full automation today.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical labs operate under strict regulatory oversight (CAP, CLIA) and quality standards that typically require a qualified human supervisor to approve task assignments and ensure competency matching. Liability for incorrect work assignment and accreditation requirements create strong barriers to full automation.
Adoption barriersclaude-sonnet-53/5No explicit licensing requirement for the coordination task itself, but supervisory responsibility often falls to certified lab personnel per accreditation/regulatory standards (e.g., CLIA), creating moderate friction.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI scheduling tools exist but still require significant human oversight, validation, and correction, limiting cost savings. The all-in cost (software licensing, integration, human oversight) often approaches or exceeds the efficiency gain versus a cytotechnologist managing assignments directly.
Cost vs. human wageclaude-sonnet-52/5Generic scheduling/workforce tools have some cost savings, but the judgment-heavy coordination and exception handling still require a human supervisor, limiting overall cost advantage.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably handles full task-assignment coordination in clinical labs at scale; existing lab scheduling software offers templates but requires manual human oversight and adjustment. Current AI lacks sufficient situational awareness of lab-specific constraints and personnel capabilities to operate end-to-end.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product manages lab staff task assignments end-to-end in cytotechnology or clinical lab settings; scheduling software exists but requires heavy human oversight and decision-making.

Prepare cell samples by applying special staining techniques, such as chromosomal staining, to differentiate cells or cell components.

18

CI 11–25 · exposure 13 · augmentation 38 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Clinical laboratory automation has grown, but staining remains largely manual in most settings outside high-throughput cancer screening centers. Adoption is slow in smaller labs and non-urban settings where cost and integration barriers are highest.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory medicine adopts automation slowly due to regulatory validation requirements, though some automated stainers are already common as hardware (not AI-driven) tools.
Augmentation potentialclaude-haiku-4-5-202510013/5AI-guided staining protocol recommendation systems and automated reagent dispensers can assist technologists by reducing manual steps and suggesting optimal staining combinations, but the human remains essential for quality control and troubleshooting of cell preparation outcomes.
Augmentation potentialclaude-sonnet-52/5AI offers limited direct assistance to the physical staining process itself, though it may help with protocol selection or quality control checks alongside the manual technique.
Task automatabilityclaude-haiku-4-5-202510012/5While automated staining systems exist and can apply reagents, the task requires judgment in selecting appropriate staining protocols, microscope preparation, and quality control—decisions that currently depend on human expertise. Automation can handle reagent application but not the full end-to-end protocol selection and validation at the ≥50% time-saving bar.
Task automatabilityclaude-sonnet-51/5This is a physical laboratory wet-lab procedure requiring manual manipulation of slides, reagents, and staining protocols that current AI systems cannot physically execute end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Cytotechnology is a licensed profession in many U.S. states, and staining is often part of quality-assurance workflows where a certified technologist must validate the samples. Liability and regulatory requirements (CLIA, CAP accreditation) create substantial friction against full automation without human sign-off.
Adoption barriersclaude-sonnet-54/5Clinical lab staining procedures are subject to CLIA/laboratory accreditation regulations requiring qualified personnel to perform and validate specimen preparation, creating substantial regulatory and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Automated staining equipment requires significant capital investment, maintenance, and integration costs, while the per-sample reagent savings are modest. For most cytology labs, the all-in cost of automation exceeds the loaded wage of a technologist performing manual staining.
Cost vs. human wageclaude-sonnet-52/5Automated staining hardware exists but requires costly lab equipment, calibration, and technician oversight, so cost savings versus a human cytotechnologist performing this specific staining step are modest at best.
Technical feasibility todayclaude-haiku-4-5-202510012/5Robotic liquid handlers and automated staining modules are deployed in some high-volume labs, but they operate within narrow, pre-validated protocols and require constant human oversight. These systems lack the flexibility to adapt staining techniques on the fly or to diagnose and correct protocol failures without intervention.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product performs physical cell staining; automation in this space is limited to laboratory robotics/autostainers, not AI systems per se, and these require significant human setup and oversight.

Maintain effective laboratory operations by adhering to standards of specimen collection, preparation, or laboratory safety.

16

CI 7–25 · exposure 13 · augmentation 38 · importance 4.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Adoption of AI-driven laboratory automation remains in early stages; while some large reference labs pilot quality-control imaging and compliance monitoring, most clinical cytology laboratories rely on traditional human-led specimen management due to regulatory requirements and the cost of modernization.
Sector adoption velocityclaude-sonnet-52/5Clinical laboratory settings adopt AI slowly for physical operational and compliance tasks, with adoption concentrated in diagnostic image analysis rather than operational safety management.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully assist cytotechnologists through automated compliance monitoring, documentation checks, specimen quality imaging analysis, and safety-alert systems, modestly raising efficiency and reducing manual paperwork without removing the human from critical decisions.
Augmentation potentialclaude-sonnet-52/5AI can assist with tracking compliance documentation, generating checklists, or flagging deviations from protocols, but it doesn't materially transform the operational task itself.
Task automatabilityclaude-haiku-4-5-202510012/5While AI could assist with monitoring safety compliance and flagging deviations from protocols, the task fundamentally requires human judgment in real-time specimen handling, physical collection procedures, and response to safety incidents. Current systems cannot reliably perform hands-on specimen preparation or enforce in-person safety practices end-to-end.
Task automatabilityclaude-sonnet-51/5This task involves physically maintaining lab operations, adhering to safety protocols, and managing specimen handling procedures, which requires hands-on physical presence and real-time judgment that AI cannot perform end-to-end today.},
Adoption barriersclaude-haiku-4-5-202510014/5Strong regulatory barriers exist: laboratory safety standards (CLIA, CAP) mandate human responsibility for specimen integrity and safety protocols, and many jurisdictions require licensed personnel to certify proper specimen collection and handling. Liability for specimen damage or safety violations creates asymmetric error costs.
Adoption barriersclaude-sonnet-54/5Laboratory safety and specimen handling are governed by regulatory and accreditation standards (CLIA, OSHA) requiring qualified human oversight and accountability, creating strong barriers to automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5The specialized nature of specimen handling, combined with regulatory oversight needs and the cost of integrating AI monitoring systems into existing laboratory workflows, makes the all-in cost comparable to or potentially higher than employing trained cytotechnologists for these critical tasks.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute performing this operational/compliance task, so cost comparison favors the human entirely.
Technical feasibility todayclaude-haiku-4-5-202510012/5Limited deployed products exist for full automation of specimen collection and preparation; computer vision systems can assist with quality checks and documentation, but production systems do not yet reliably replace human oversight of specimen integrity, safety protocols, or environmental conditions in working laboratories.
Technical feasibility todayclaude-sonnet-51/5No deployed AI product manages laboratory operations, safety compliance, and specimen handling adherence in production; this remains a human operational and physical responsibility.

Adjust, maintain, or repair laboratory equipment, such as microscopes.

7

CI 5–10 · exposure 0 · augmentation 25 · importance 4.1/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Laboratory equipment maintenance remains highly localized, hands-on work performed by technicians in low-automation sectors; adoption of autonomous repair systems is negligible, and regulatory/liability constraints slow any potential shift.
Sector adoption velocityclaude-sonnet-51/5Physical equipment maintenance in clinical laboratory settings shows minimal AI or robotic adoption, as this remains a manual, low-digitization task.
Augmentation potentialclaude-haiku-4-5-202510012/5AI could assist by analyzing equipment logs or recommending troubleshooting steps, but the core task—physical adjustment and repair—cannot be augmented meaningfully without removing the human from the loop entirely.
Augmentation potentialclaude-sonnet-52/5AI could assist with diagnostic troubleshooting guides or scheduling maintenance reminders, but offers little direct help with the physical act of adjusting or repairing equipment.
Task automatabilityclaude-haiku-4-5-202510011/5Microscope adjustment, maintenance, and repair require physical manipulation in 3D space, diagnostics of complex optical/mechanical systems, and judgment about when components need service—capabilities far beyond current AI. No end-to-end automation exists for this hands-on technical work.
Task automatabilityclaude-sonnet-51/5Physical adjustment and repair of microscopes and lab equipment requires manual dexterity and hands-on diagnosis that current AI systems cannot perform without embodiment in capable robotics, which is not generally available.
Adoption barriersclaude-haiku-4-5-202510014/5Significant barriers exist: equipment manufacturers often restrict repairs to certified technicians for warranty and liability reasons, regulatory compliance is required, and many facilities must maintain service contracts with licensed vendors rather than use third-party automation.
Adoption barriersclaude-sonnet-53/5While no formal licensing is typically required to maintain microscopes, safety and equipment liability concerns mean labs still prefer trained personnel or manufacturer service technicians.
Cost vs. human wageclaude-haiku-4-5-202510011/5Specialized technicians command significant labor cost, and any robotic system capable of microscope repair would require substantial capital investment, integration, and maintenance—making it far more expensive than human expertise per repair event.
Cost vs. human wageclaude-sonnet-51/5There is no viable AI substitute for physical repair work, so any AI-based approach would require robotic hardware far more costly than the human labor it would replace.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI products perform microscope maintenance and repair autonomously in production. Robotic systems for laboratory equipment service are research-stage and extremely narrow in scope, not reliable or available at scale.
Technical feasibility todayclaude-sonnet-51/5No deployed products perform physical maintenance or repair of laboratory microscopes; this remains a manual task performed by technicians or specialized repair services.

Assist pathologists or other physicians to collect cell samples by fine needle aspiration (FNA) biopsy or other method.

0

CI 0–0 · exposure 0 · augmentation 25 · importance 4.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Healthcare remains a conservative, highly regulated sector with slow adoption of unproven clinical automation. No evidence of meaningful production deployment of autonomous FNA biopsy systems in clinical settings exists.
Sector adoption velocityclaude-sonnet-51/5Physical, hands-on clinical procedure assistance in healthcare settings sees minimal AI adoption due to the nature of the task requiring in-person human physical presence and dexterity.
Augmentation potentialclaude-haiku-4-5-202510012/5AI may assist by guiding needle placement through real-time imaging analysis or pre-procedure planning, but the clinical practitioner must retain direct control of the invasive procedure itself, limiting the scope of augmentation.
Augmentation potentialclaude-sonnet-52/5AI may assist with image analysis or documentation adjacent to the procedure, but offers minimal direct augmentation to the physical act of assisting in sample collection itself.
Task automatabilityclaude-haiku-4-5-202510011/5Fine needle aspiration biopsy is an invasive clinical procedure requiring real-time anatomical navigation, patient interaction, and sterile technique. Current AI systems cannot perform the physical manipulation, positioning, and needle insertion that this task fundamentally requires.
Task automatabilityclaude-sonnet-51/5This is a hands-on clinical procedure involving physical patient contact, needle guidance, and real-time coordination with a physician, none of which current AI systems can perform.It requires physical manipulation and human dexterity that off-the-shelf AI cannot replicate.
Adoption barriersclaude-haiku-4-5-202510015/5This task is inherently protected by multiple hard barriers: it requires a licensed healthcare provider to perform or directly supervise the invasive procedure, involves direct patient contact and informed consent, and carries significant liability and regulatory oversight under medical practice acts.
Adoption barriersclaude-sonnet-55/5This involves direct patient contact and invasive medical procedures requiring licensed personnel, strict regulatory oversight, and liability considerations that legally require human involvement.
Cost vs. human wageclaude-haiku-4-5-202510011/5The equipment, integration, and oversight costs for any robotic FNA system would far exceed the labor cost of a trained cytotechnologist or physician performing the procedure, making automation economically infeasible today.
Cost vs. human wageclaude-sonnet-51/5There is no AI system capable of performing this physical assistive role, so no meaningful cost comparison exists; the human is the only viable option.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product performs fine needle aspiration biopsy independently. This task requires embodied robotics with real-time ultrasound or imaging feedback in a clinical setting, which remains largely experimental and not reliable for routine clinical use.
Technical feasibility todayclaude-sonnet-51/5No deployed product performs physical assistance in FNA biopsy procedures; this remains entirely a human physical task with no robotic or AI substitute in clinical production use.

Attend continuing education programs that address laboratory issues.

0

CI 0–0 · exposure 0 · augmentation 38 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5This is a regulated professional requirement that cannot be displaced by AI. Adoption velocity is irrelevant since the barrier is absolute and regulatory, not subject to market forces.
Sector adoption velocityclaude-sonnet-51/5This is a compliance/administrative activity tied to professional licensure, an area with essentially no AI displacement trend.
Augmentation potentialclaude-haiku-4-5-202510012/5AI could marginally assist by summarizing course materials, generating study guides, or recommending relevant programs, but the core task of attending and engaging in education must remain human-centered. Limited supplementary value.
Augmentation potentialclaude-sonnet-53/5AI can help find relevant courses, summarize content, or generate study aids, providing moderate assistance to the learning process itself.
Task automatabilityclaude-haiku-4-5-202510011/5Attending continuing education programs requires human presence, engagement, and assessment of domain-specific material. AI cannot meaningfully replace the cognitive work of learning new laboratory protocols, regulatory updates, or professional development in real-time educational settings.
Task automatabilityclaude-sonnet-51/5Attending continuing education is inherently a human learning and compliance activity; AI cannot 'attend' or fulfill certification requirements on someone's behalf.
Adoption barriersclaude-haiku-4-5-202510015/5Professional licensing bodies (e.g., ASCP) mandate continuing education hours as a legal requirement for cytotechnologists to maintain certification. The human must personally complete these hours; no substitution is legally permissible.
Adoption barriersclaude-sonnet-55/5Continuing education requirements are typically mandated by licensing/certification bodies (e.g., ASCP) and must be completed personally by the credentialed professional.
Cost vs. human wageclaude-haiku-4-5-202510011/5The task involves human time investment in professional development; AI has no direct cost advantage since the human must attend regardless. Automating attendance is not possible, making cost comparison inapplicable.
Cost vs. human wageclaude-sonnet-51/5There is no AI service that replaces this task, so cost comparison favors the human by default.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed AI product can autonomously attend educational programs or fulfill the professional/regulatory requirement for cytotechnologists to personally participate in continuing education. This task inherently requires human presence and active learning.
Technical feasibility todayclaude-sonnet-51/5No deployed product substitutes for a human's mandatory continuing education attendance in this credentialed field.

Related occupations — Healthcare Practitioners & Technical

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.